Reversal of rocuronium induced neuromuscular block by sugammadex for electroconvulsive therapy; crossover designed dose response study

Reversal of rocuronium induced neuromuscular block by sugammadex for electroconvulsive therapy; crossover designed dose response study - Reversal of rocuronium induced neuromuscular block by sugammadex for electroconvulsive therapy; crossover designed dose response study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007254

Enrollment

Registered

2012-02-21

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric disease

Interventions

To evaluate dose response muscular blockade reversal effect, 2 mg/kg of sugammadex will be assigned. To evaluate dose response muscular blockade reversal effect, 4 mg/kg of sugammadex will be assigned

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who will be planned electroconvulsive therapy 2. Patients who are capable of providing written informed consent.

Exclusion criteria

Exclusion criteria: Patients seems inadequate for this study by investigators

Design outcomes

Primary

Measure	Time frame
Reversal effect of sugammadex for rocuronium induced neuromuscular block	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026